Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Huang, Yi  [Clear All Filters]
Journal Article
Wang J, Zhang C, Huang Y, Ruan Y, Hu Y, Wang J, Wang F, Yu M, Xu Y, Liu L, et al. Parallel genome-wide CRISPR screens to identify state-dependent self-renewal regulators of mouse embryonic stem cells. Stem Cells Dev. 2023.
Wang B, Li C, Ming J, Wu L, Fang S, Huang Y, Lin L, Liu H, Kuang J, Zhao C, et al. The NuRD complex cooperates with SALL4 to orchestrate reprogramming. Nat Commun. 2023;14(1):2846.
Ruan Y, Wang J, Yu M, Wang F, Wang J, Xu Y, Liu L, Cheng Y, Yang R, Zhang C, et al. A multi-omics integrative analysis based on CRISPR screens re-defines the pluripotency regulatory network in ESCs. Commun Biol. 2023;6(1):410.
Chu J, Li Y, Fan X, Ma J, Li J, Lu G, Zhang Y, Huang Y, Li W, Huang X, et al. MiR-4319 Suppress the Malignancy of Triple-Negative Breast Cancer by Regulating Self-Renewal and Tumorigenesis of Stem Cells. Cell Physiol Biochem. 2018;48(2):593-604.
Nian W, Ao X, Wu Y, Huang Y, Shao J, Wang Y, Chen Z, Chen F, Wang D. miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2. Oncol Lett. 2013;6(2):359-366.
Wang J, Huang Y, Zhang C, Ruan Y, Tian Y, Wang F, Xu Y, Yu M, Wang J, Cheng Y, et al. Identification and functional evaluation of alternative splice variants of Dax1 in mouse embryonic stem cells. Stem Cells Dev. 2023.
Wang G, Huang Y, Yang F, Tian X, Wang K, Liu L, Fan Y, Li X, Li L, Shi B, et al. High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer. Aging (Albany NY). 2020;12.
Li Y, Chu J, Feng W, Yang M, Zhang Y, Zhang Y, Qin Y, Xu J, Li J, Vasilatos SN, et al. EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties. FASEB J. 2019:fj201701561RRRR.
Zhang H, Wang J, Ren T, Huang Y, Liang X, Yu Y, Wang W, Niu J, Guo W. Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B. Cancer Lett. 2020.